183 related articles for article (PubMed ID: 7908199)
1. [Detection of somatostatin receptors in tumors in the area of the head and neck and their clinical importance].
Kau RJ; Wagner-Manslau C; Saumweber DM; Arnold W
Laryngorhinootologie; 1994 Jan; 73(1):21-6. PubMed ID: 7908199
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptor scintigraphy and therapy of neuroendocrine (APUD) tumors of the head and neck.
Kau R; Arnold W
Acta Otolaryngol; 1996 Mar; 116(2):345-9. PubMed ID: 8725546
[TBL] [Abstract][Full Text] [Related]
3. 111In-pentetreotide scintigraphy is superior to 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma.
Muros MA; Llamas-Elvira JM; Rodríguez A; Ramírez A; Gómez M; Arráez MA; Valéncia E; Vílchez R
Nucl Med Commun; 1998 Aug; 19(8):735-42. PubMed ID: 9751927
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of somatostatin receptor imaging in patients with suspected head and neck paragangliomas.
Schmidt M; Fischer E; Dietlein M; Michel O; Weber K; Moka D; Stennert E; Schicha H
Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1571-80. PubMed ID: 12458390
[TBL] [Abstract][Full Text] [Related]
5. 111Indium pentetreotide imaging in the evaluation of head and neck tumors.
Myssiorek D; Tronco G
Laryngoscope; 2005 Oct; 115(10):1707-16. PubMed ID: 16222183
[TBL] [Abstract][Full Text] [Related]
6. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
8. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
9. Imaging of bronchial carcinoid tumours with indium-111 pentetreotide.
O'Byrne KJ; O'Hare NJ; Freyne PJ; Luke DA; Clancy LJ; Prichard JS; Carney DN
Thorax; 1994 Mar; 49(3):284-6. PubMed ID: 7911261
[TBL] [Abstract][Full Text] [Related]
10. Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours.
Oberg K; Eriksson B
Best Pract Res Clin Endocrinol Metab; 2005 Jun; 19(2):265-76. PubMed ID: 15763700
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck.
Duet M; Sauvaget E; Pételle B; Rizzo N; Guichard JP; Wassef M; Le Cloirec J; Herman P; Tran Ba Huy P
J Nucl Med; 2003 Nov; 44(11):1767-74. PubMed ID: 14602858
[TBL] [Abstract][Full Text] [Related]
12. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.
Slooter GD; Mearadji A; Breeman WA; Marquet RL; de Jong M; Krenning EP; van Eijck CH
Br J Surg; 2001 Jan; 88(1):31-40. PubMed ID: 11136306
[TBL] [Abstract][Full Text] [Related]
14. Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.
Chiti A; van Graafeiland BJ; Savelli G; Ferrari L; Seregni E; Castellani MR; Bombardieri E
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S190-4. PubMed ID: 10604128
[TBL] [Abstract][Full Text] [Related]
15. Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.
Dörr U; Räth U; Sautter-Bihl ML; Guzman G; Bach D; Adrian HJ; Bihl H
Eur J Nucl Med; 1993 May; 20(5):431-3. PubMed ID: 8100192
[TBL] [Abstract][Full Text] [Related]
16. Radiolabelled somatostatin analogue scintigraphy in oncology.
O'Byrne KJ; Carney DN
Anticancer Drugs; 1996 Jan; 7 Suppl 1():33-44. PubMed ID: 8822083
[TBL] [Abstract][Full Text] [Related]
17. Metastatic carcinoid tumor imaged with CT and a radiolabeled somatostatin analog: a case report.
Lobrano MB; McCarthy K; Adams L; Neitzschman H
Am J Gastroenterol; 1997 Mar; 92(3):513-5. PubMed ID: 9068482
[TBL] [Abstract][Full Text] [Related]
18. Incremental diagnostic value and impact on patient management of somatostatin receptor scintigraphy with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors.
Usmani S; Khan HA; Abdulla M; Ahmed N; abu Huda F; Marafi F; al Kandari F; al Mohannadi S; al Nafisi N
Med Princ Pract; 2011; 20(4):356-61. PubMed ID: 21576997
[TBL] [Abstract][Full Text] [Related]
19. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
20. Octreotide scanning for carcinoid tumours.
Critchley M
Postgrad Med J; 1997 Jul; 73(861):399-402. PubMed ID: 9338023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]